Evidence map›Paper›PMID 28353077›Full record

ReviewCurrent hypertension reports2017

Role of Orexin-A in Hypertension and Obesity.

Roberta Imperatore, Letizia Palomba, Luigia Cristino

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hypertension reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. The Effectiveness ofVascular health and risk management · 2023
    Article
  13. Prenatal Effects of Nicotine on Obesity Risks: A Narrative Review.International journal of environmental research and public health · 2022
    Review
  14. The association between blast exposure and transdiagnostic health symptoms on systemic inflammation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Article
  15. Pediatric Narcolepsy-A Practical Review.Children (Basel, Switzerland) · 2022
    Review
  16. Article
  17. Recent Progress of Chronic Stress in the Development of Atherosclerosis.Oxidative medicine and cellular longevity · 2022
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Roberta ImperatoreEndocannabinoid Research Group, Institute of Biomolecular Chemistry, CNR, Viale Campi Flegrei, 80078, Pozzuoli, Italy.
Letizia PalombaDepartment of Biomolecular Science, University of Urbino "Carlo Bo", Urbino, Italy.
Luigia CristinoEndocannabinoid Research Group, Institute of Biomolecular Chemistry, CNR, Viale Campi Flegrei, 80078, Pozzuoli, Italy. luigia.cristino@icb.cnr.it.
University of Sannio · ITUniversity of Urbino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewHypertension is one of the most challenging health problems inducing cerebrovascular disease and high percentage of death when associated with diabetes, dyslipidemias, and obesity. Orexin/hypocretin is a peptide expressed by a small number of neurons of the dorsolateral hypothalamus, a brain feeding and autonomic "fight-or-flight" regulatory center. According to this function, orexin has been demonstrated to evoke cardiovascular responses, heart rate, hypertension, hyperarousal, hyperphagia, and obesity. The focus of this review is to provide an overview about the mechanism through which orexin regulates food intake and cardiovascular responses and its role in the pathogenesis of obesity and hypertension which could be of great interest to establish possible new therapies. RECENT

findingsIn normal rats and mice, central administration of orexin increases food intake, blood pressure, and sympathetic nerve activity and these effects are blocked by selective orexin receptor antagonist SB-334867 or almorexant. Moreover, upregulation of orexin signaling, in combination with elevation of epinephrine and norepinephrine circulating levels, occurs in rats exposed to chronic stress, in models of spontaneous hypertension (SHR and BPH/2J Schlager mice) and in obese mice (ob/ob or mice fed with high fat diet). Therefore, hyperactivity of orexinergic neurons could be a factor in the development of obesity and essential hypertension. Because of their widespread projections to the brain regions involved in appetite and cardiovascular responses, as far down as sympathetic preganglionic neurons in the spinal cord, orexin evokes sympathetically mediated cardiovascular responses. Lasting upregulation of orexin signaling can lead to hyperphagia, obesity, and hypertensive state. Dual orexin receptor antagonists (DORAs) and selective orexin receptor antagonists (SORAs) have antihypertensive effects that could be of clinical use for regulation of food intake and hypertension, supporting the role of orexinergic neurons as critical checkpoint in the neurogenic control of metabolic and cardiovascular functions.

Indexed as

AnimalsBlood PressureHumansHypertensionObesityOrexin ReceptorsOrexinsSympathetic Nervous SystemOrexin ReceptorsOrexinsCatecholamineEpinephrineHypertensionNorepinephrineObesityOrexin

Identifiers

PMID28353077
OpenAlexW2598788731

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.